Download Files:

IT1t (dihydrochloride)

$102$1,128

Products Details

Product Description

– IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.

Web ID

– HY-101458A

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– COVID-19-anti-virus

Molecular Formula

– C21H36Cl2N4S2

References

– [1]Van Hout A, et al. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS One. 2017 Apr 14;12(4):e0176057.|[2]Wu B, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010 Nov 19;330(6007):1066-71.|[3]Tulotta C, et al. Inhibition of signaling between human CXCR4 and zebrafish ligands by the small molecule IT1timpairs the formation of triple-negative breast cancer early metastases in a zebrafish xenograft model. Dis Model Mech. 2016 Feb;9(2):141-53.

CAS Number

– 1092776-63-0

Molecular Weight

– 479.57

Compound Purity

– 99.89

SMILES

– CC1(C)CN2C(CS/C(NC3CCCCC3)=NC4CCCCC4)=CSC2=N1.[H]Cl.[H]Cl

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology; Endocrinology; Cancer

Solubility

– DMSO : ≥ 30 mg/mL|H2O : 50 mg/mL (ultrasonic)

Target

– CXCR;HIV

Isoform

– CXCR4;HIV-1

Pathway

– Anti-infection;GPCR/G Protein;Immunology/Inflammation

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.